Top

Published in:

Open Access 01-12-2021 | Multiple Sclerosis | Research

Assessing multiple sclerosis-related quality of life among Iranian patients using the MSQOL-54 tool: a cross-sectional study

Authors: Shadi Ziaie, Niloofar Namazi, Golnaz Afzal, Saghar Barati, Rezvaneh Mohebbi, Mahshad Mir, Hadi Esmaily, Gholamhossein Mehralian

Published in: BMC Neurology | Issue 1/2021

Abstract

Background

Multiple sclerosis (MS) is a chronic autoimmune disease and is one of the most costly medical conditions that imposed families with catastrophic health expenditures. There is an increasing trend in using alternative medicines including, dietary supplements, herbs, vitamins, and minerals. To date, the association between dietary as well as herbal supplements and QoL in MS patients is under researched; thus, this study aimed to assess the association between the self-reported supplement used and QoL between MS patients.

Methods

This cross-sectional study was conducted on patients with MS referring to Shahid Kazemi Pharmacy, based in the city of Tehran, Iran, as a national pharmacy providing specialized pharmaceutical products and pharmaceutical care to patients. The Multiple Sclerosis Quality of Life-54 (MSQoL-54) tools was performed to evaluate MS patients QoL.

Results

A total number of 382 patients with MS participated in this study. They include 89 (23.3%) men and 293 (76.7%) women, aged 40 ± 10.9 years old. The overall score of the MSQoL-54 questionnaire was 41.58 out of 100. Physical health composite (PHC) and mental health composite (MHC) were 69.60 and 62.99 from 100, respectively. This study revealed that 76.4% of patients used at least one vitamin daily; 92.4% of patients do not receive any herbal product. Vitamin D is the most widely used supplement, followed by calcium, while vitamin C is the least consumed. No correlation was observed regarding supplement use and overall QoL, PHC, or MHC. There were no significant differences between QoL’s dimensions score in patients who used supplements. The results showed that increasing the number of supplements used did not relate to overall QoL, PHC, or MHC. In addition, there was not any correlation between the duration used of supplements and QoL’s dimensions score in MS patients (p-value> 0.05).

Conclusions

The dietary supplement appears to be popular among MS patients. The study results showed that the number of supplementations and their long-term use in patients with MS were not associated with higher QoL. Similarly, the herbal supplements have failed to improve QoL.

Berer K, Krishnamoorthy G. Microbial view of central nervous system autoimmunity. FEBS Lett. 2014;588(22):4207–13. https://doi.org/10.1016/j.febslet.2014.04.007.

Sahraian MA, Sahebkar M, Dehghani R, Derakhshan-Jazari M, Kazami-Moghaddam V, Kouchaki E. Multiple sclerosis-a disease on a dramatically rising trend in Iran: review of possible reasons. Iran J Neurol. 2017;16(1):34–40.

Jones E, Pike J, Marshall T, Ye X. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US. BMC Health Serv Res. 2016;16(1):294. https://doi.org/10.1186/s12913-016-1532-1.

Wallin MT, Culpepper WJ, Nichols E, Bhutta ZA, Gebrehiwot TT, Hay SI, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(3):269–85. https://doi.org/10.1016/S1474-4422(18)30443-5.CrossRef

Azami M, YektaKooshali MH, Shohani M, Khorshidi A, Mahmudi L. Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis. PLoS One. 2019;14(4):e0214738-e.CrossRef

Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31(6):752–9. https://doi.org/10.1097/WCO.0000000000000622.CrossRefPubMed

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BA, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. 2018;90(17):777–88. https://doi.org/10.1212/WNL.0000000000005347.

Macías Islas MÁ, Ciampi E. Assessment and impact of cognitive impairment in multiple sclerosis: an overview. Biomedicines. 2019;7(1):22. https://doi.org/10.3390/biomedicines7010022.CrossRefPubMedCentral

Jongen PJ, Heerings M, Ruimschotel R, Hussaarts A, Duyverman L, van der Zande A, et al. Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later. BMC Res Notes. 2016;9(1):375. https://doi.org/10.1186/s13104-016-2173-5.

10.

Sarısoy G, Terzi M, Gümüş K, Pazvantoğlu O. Psychiatric symptoms in patients with multiple sclerosis. Gen Hosp Psychiatry. 2013;35(2):134–40. https://doi.org/10.1016/j.genhosppsych.2012.10.011.CrossRefPubMed

11.

Jongen PJ. Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2017;31(7):585–602. https://doi.org/10.1007/s40263-017-0444-x.CrossRefPubMedPubMedCentral

12.

Bandari DS, Vollmer TL, Khatri BO, Tyry T. Assessing quality of life in patients with multiple sclerosis. Int J MS Care. 2010;12(1):34–41. https://doi.org/10.7224/1537-2073-12.1.34.CrossRef

13.

Mitchell AJ, Benito-León J, González J-MM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005;4(9):556–66. https://doi.org/10.1016/S1474-4422(05)70166-6.CrossRefPubMed

14.

Greenhalgh J, Long AF, Flynn R. The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory? Soc Sci Med. 2005;60(4):833–43. https://doi.org/10.1016/j.socscimed.2004.06.022.CrossRefPubMed

15.

Tryfonos C, Mantzorou M, Fotiou D, Vrizas M, Vadikolias K, Pavlidou E, et al. Dietary supplements on controlling multiple sclerosis symptoms and relapses: current clinical evidence and future perspectives. Medicines (Basel). 2019;6(3):95. https://doi.org/10.3390/medicines6030095.CrossRef

16.

O’Connor K, Weinstock-Guttman B, Carl E, Kilanowski C, Zivadinov R, Ramanathan MJJon. Patterns of dietary and herbal supplement use by multiple sclerosis patients. J Neurol. 2012;259(4):637–44.

17.

Alnahdi MA, Alsulayhim AK, Salem AHB, Masuadi E, Malik YA. Patterns and outcomes of complementary and alternative medicine use among adult patients with multiple sclerosis. Cureus. 2020;12(10):e10825. https://doi.org/10.7759/cureus.10825.

18.

Yadav V, Shinto L, Bourdette D. Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Rev Clin Immunol. 2010;6(3):381–95.

19.

Olsen S. A review of complementary and alternative medicine (CAM) by people with multiple sclerosis. Occup Ther Int. 2009;16(1):57–70.

20.

Ernstsson O, Gyllensten H, Alexanderson K, Tinghög P, Friberg E, Norlund A. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11(7):e0159129. https://doi.org/10.1371/journal.pone.0159129.

21.

McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple sclerosis in the UK: service use, costs, quality of life and disability. PharmacoEconomics. 2008;26(10):847–60. https://doi.org/10.2165/00019053-200826100-00005.CrossRefPubMed

22.

Rotstein Z, Hazan R, Barak Y, Achiron A. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis. Autoimmun Rev. 2006;5(8):511–6. https://doi.org/10.1016/j.autrev.2006.02.001.CrossRefPubMed

23.

Kobelt G. Costs and quality of life of patients with multiple sclerosis in Europe. The Euro J Health Econ. 2006;7(Suppl 2):S24–33.CrossRef

24.

Sanoobar M, Dehghan P, Khalili M, Azimi A, Seifar F. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: a double blind randomized clinical trial. Nutr Neurosci. 2016;19(3):138–43. https://doi.org/10.1179/1476830515Y.0000000002.CrossRefPubMed

25.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Multiple sclerosis (Houndmills, Basingstoke, England). 2016;22(13):1719–31.CrossRef

26.

Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Nafissi S, Togha M, Beladi Moghadam N, et al. Impact of vitamin a supplementation on disease progression in patients with multiple sclerosis. Arch Iranian Med. 2015;18(7):435–40 DOI: 0151807/AIM.008.

27.

Toghianifar N, Ashtari F, Zarkesh-Esfahani SH, Mansourian M. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. J Neuroimmunol. 2015;285:125–8. https://doi.org/10.1016/j.jneuroim.2015.05.022.CrossRefPubMed

28.

Nozari E, Ghavamzadeh S, Razazian N. The effect of vitamin B12 and folic acid supplementation on serum homocysteine, Anemia status and quality of life of patients with multiple sclerosis. Clin Nutr Res. 2019;8(1):36–45. https://doi.org/10.7762/cnr.2019.8.1.36.CrossRefPubMedPubMedCentral

29.

Simpson-Yap S, Jelinek P, Weiland T, Nag N, Neate S, Jelinek G. Self-reported use of vitamin D supplements is associated with higher physical quality of life scores in multiple sclerosis. Mult Scler Relat Disord. 2021;49:102760. https://doi.org/10.1016/j.msard.2021.102760.CrossRefPubMed

30.

Goldberg P, Fleming M, Picard E. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses. 1986;21(2):193–200.

31.

Rezapour A, Kia AA, Goodarzi S, Hasoumi M, Motlagh SN, Vahedi S. The impact of disease characteristics on multiple sclerosis patients’ quality of life. Epidemiol Health. 2017;39. https://doi.org/10.4178/epih.e201700.

32.

Nedjat S, Montazeri A, Mohammad K, Majdzadeh R, Nabavi N, Nedjat F, et al. Quality of life in multiple sclerosis compared to the healthy population in Tehran. Iran J Epidemiol. 2006;2(3):19–24.

33.

Opara JA, Jaracz K, Brola W. Quality of life in multiple sclerosis. J Med Life. 2010;3(4):352–8.PubMedPubMedCentral

34.

Ibrahim EAAE, Gassoum A, IshagAgib IEI. Quality of life among Sudanese patients with multiple sclerosis in Khartoum state using (MSQoL-54) questionnaire. BMC Res Notes. 2019;12(1):1–4.CrossRef

35.

Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995;4(3):187–206. https://doi.org/10.1007/BF02260859.CrossRefPubMed

36.

Ghaem H, Haghighi AB, Jafari P, Nikseresht A. Validity and reliability of the Persian version of the multiple sclerosis quality of life questionnaire. Neurol India. 2007;55(4):369–75. https://doi.org/10.4103/0028-3886.33316.CrossRefPubMed

37.

Abonie US, Hoekstra F, Seves BL, Woude LH, Dekker R, Hettinga F. Associations between Activity Pacing, Fatigue, and Physical Activity in Adults with Multiple Sclerosis: A Cross Sectional Study. J Funct Morphol Kinesiol. 2020;5(2):43.

38.

Beckerman H, de Groot V, Scholten MA, Kempen JCE, Lankhorst GJ. Physical activity behavior of people with multiple sclerosis: understanding how they can become more physically active. Phys Ther. 2010;90(7):1001–13. https://doi.org/10.2522/ptj.20090345.CrossRefPubMed

39.

Wendel-Vos GCW, Schuit AJ, Saris WHM, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56(12):1163–9. https://doi.org/10.1016/S0895-4356(03)00220-8.CrossRefPubMed

40.

Mohammadi M, Rashidizad SA, Lashkari N, Ataei S, Haddadi R, Mahboobian MM. Supplement Therapy in Multiple Sclerosis: A Pharmacological View. Avicenna J Pharm Res. 2020;1(1):37–45.

41.

Leong E M, Semple S J, Angley M, Siebert W, Petkov J, McKinnon RA. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why?. Complement Ther Med. 2009;17(4):216–23.

42.

Yadav V, Shinto L, Morris C, Senders A, Baldauf-Wagner S, Bourdette Dennis. Use and self-reported benefit of complementary and alternative medicine among multiple sclerosis patients. Int J MS Care. 2006;8(1):5–10.

43.

Nayak S, Matheis RJ, Schoenberger NE, SCJCr S. Use of unconventional therapies by individuals with multiple sclerosis. 2003;17(2):181–91.

44.

Bagur MJ, Murcia MA, Jiménez-Monreal AM, Tur JA, Bibiloni MM, Alonso GL, et al. Influence of diet in multiple sclerosis: a systematic review. Adv Nutr. 2017;8(3):463–72. https://doi.org/10.3945/an.116.014191.CrossRefPubMedPubMedCentral

45.

Achiron A, Givon U, Magalashvili D, Dolev M, Zaltzman S L, Kalron A, et al. Effect of Alfacalcidol on multiple sclerosisrelated fatigue: A randomized, double-blind placebo-controlled study. Mult Scler. 2015;21(6):767–75.

46.

Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M. Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation. 2015;22(6):400–4.

47.

Miclea A, Bagnoud M, Chan A, Hoepner R. A Brief Review of the Effects of Vitamin D on Multiple Sclerosis. Front Immunol. 2020;11:781. https://doi.org/10.3389/fimmu.2020.00781.eCollection2020.

48.

Bhargava P, Steele SU, Waubant E, Revirajan NR, Marcus J, Dembele M, et al. Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. Mult Scler J. 2016;22(6):753–60. https://doi.org/10.1177/1352458515600248.CrossRef

49.

Bhargava P, Fitzgerald KC, Calabresi PA, Mowry EM. Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. JCI Insight. 2017;2(19):e95302. 10.1172/jci.insight.95302.

50.

Kim E, Cameron M, Lovera J, Schaben L, Bourdette D, RJMSJ W. American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study. 2011;17(12):1523–6. https://doi.org/10.1177/1352458511412062.

51.

Etemadifar M, Sayahi F, Abtahi S-H, Shemshaki H, Dorooshi G-A, Goodarzi M, et al. Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study. 2013;123(7):480–6.

52.

O'Connor K, Weinstock-Guttman B, Carl E, Kilanowski C, Zivadinov R, Ramanathan M. Patterns of dietary and herbal supplement use by multiple sclerosis patients. J Neurol. 2012;259(4):637–44. https://doi.org/10.1007/s00415-011-6226-3.CrossRefPubMed

53.

Loraschi A, Bellantonio P, Bortolon F, Capra R, Cavalla P, Costantino G, et al. Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. Neurol Sci. 2016;37(4):613–22. https://doi.org/10.1007/s10072-016-2519-8.CrossRefPubMed

54.

Kennedy DA, Seely D. Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin Drug Saf. 2010;9(1):79–124. https://doi.org/10.1517/14740330903405593.CrossRefPubMed

55.

Kes VB, Cengić L, Cesarik M, Tomas AJ, Zavoreo I, Matovina LZ, et al. Quality of life in patients with multiple sclerosis. Acta Clin Croat. 2013;52(1):107–11.

56.

Motl RW, McAuley E, Snook EM, Gliottoni RC. Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. Psychol Health Med. 2009;14(1):111–24.

57.

Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with ω-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids. 2005;73(5):397–404.

58.

Ramsaransing GS, Mellema SA, De Keyser J. Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study. Nutr J. 2009;8(1):36. https://doi.org/10.1186/1475-2891-8-36.CrossRefPubMedPubMedCentral

59.

Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(5):S139.

60.

Lysandropoulos A, Havrdova E. ‘Hidden’factors influencing quality of life in patients with multiple sclerosis. Eur J Neurol. 2015;22:28–33. https://doi.org/10.1111/ene.12801.CrossRefPubMed

61.

Marrie RA, Patten SB, Berrigan LI, Tremlett H, Wolfson C, Warren S, et al. Diagnoses of depression and anxiety versus current symptoms and quality of life in multiple sclerosis. Int J MS Care. 2018;20(2):76–84.

Title: Assessing multiple sclerosis-related quality of life among Iranian patients using the MSQOL-54 tool: a cross-sectional study
Authors: Shadi Ziaie
Niloofar Namazi
Golnaz Afzal
Saghar Barati
Rezvaneh Mohebbi
Mahshad Mir
Hadi Esmaily
Gholamhossein Mehralian
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Multiple Sclerosis
Published in: BMC Neurology / Issue 1/2021
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02357-8

2024 ASCO Annual Meeting

Springer Medicine

Assessing multiple sclerosis-related quality of life among Iranian patients using the MSQOL-54 tool: a cross-sectional study

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Reversible splenial lesion syndrome with mental disorders as only manifestation

Case Report of a pathologically confirmed vascular parkinsonism with early cognitive impairment and Behavioral disturbance

Plasma D-dimer level is associated with clinical outcomes in patients with atrial fibrillation related acute ischemic stroke after pneumonia

Hemichorea in a patient with ipsilateral cortical infarction: a case report

Venous hypertension caused by a meningioma involving the sigmoid sinus: case report

The thalamus in trigeminal neuralgia: structural and metabolic abnormalities, and influence on surgical response